Trial | The Knowledge Dynasty

Trial

Reduction of effective dose of statins, by liver targeting delivery, could be a way to bring the drugs to the prevention market – proof-of-concept trial by Lycotec Ltd.


Statins are one of the most successful drugs able to slow down the formation of cholesterol-rich atherosclerotic plaques on the arterial walls, and reduce the development of and mortality from coronary heart disease, CHD.

Although their efficacy in management of elevated LDL cholesterol and CHD is not questionable, recommendation of their use for preventative purposes for healthy people or even borderline conditions is a subject of an ongoing strong debate.

Statins like many other drugs have their own side-effects. The use of them for people with elevated cholesterol or with already established CHD overpowers these side-effects. However, the use of statins for preventative purposes with possibilities to develop, albeit not too frequent, but still negative reactions, remains controversial.

The main reason behind the side-effects is the distribution and accumulation of statins outside their main target, the liver, into skeletal muscles or other organs.

Lycotec Ltd., the Cambridge UK based biotech company has developed and patented liver targeting oral delivery technology, LycosomeTM – http://www.lycotec.com

Based on this technology, the company has created a prototype, LycoStatinTM.

In a double blind study 40 volunteers with elevated LDL cholesterol were randomised and distributed in 5 groups with 8 participants each. The first three groups received daily either 20, or 40 or 80 mg of Simvastatin. The fourth group received LycoStatinTM containing 20 mg of Simvastatin. and the fifth group received a control lycopene, the carotenoid with is used to make Lycosomes, in the same dose as in the fourth group.

After one month of the trial it was shown that the level of the reduction of LDL cholesterol in the fourth group was significantly stronger than in the groups taking 20 or 40 mg of Simvastatin, and was at the same level as in the group which was taking 80 mg of the drug. There were no changes in LDL level in the fifth group.

These preliminary results indicate that the liver targeting delivery could increase the efficacy of statins, by apparent reduction of their random distribution to other organs, which are not involved in LDL synthesis, hence potentially minimise the side-effects of these drugs.

Some results of this trial have now been published in a peer review journal as a State of the Art Paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424257/pdf/AMS-11-25022.pdf

Later this week the Lycotec team, Dr Ivan Petyaev and Dr Yuiry Bashmakov, will present the LycoStatinTM at the World Liver Targeting Conference in Malta: http://www.targeting-liver.com

The company believes that reducing the effective dose of statins, minimising their potential side-effects, would allow these drugs, which have already saved millions of lives of people with CHD, to expand their benefit to even more millions of healthy people to prevent the development of this dominating killer disease in the developed world.

Lycotec is now looking for pharmaceutical industry partnership to further develop LycoStatin and bring it, and its potential range, to the CHD preventative market.







Related Technology Press Releases

Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence

CAMBRIDGE, Mass. (PRWEB) April 16, 2015

Cambridge Semantics, the leading provider of smart data solutions driven by Semantic Web technology, and Informa, the leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities, today announced that its joint solution ‘Smart Data Lake for Clinical Trial and Competitive Intelligence’ was named a finalist for the 2015 Bio-IT ‘Best of Show’ Award.

The solution combines Informa’s rich content sources including Citeline and Sagient, with Cambridge Semantics Anzo Smart Data Platform, enabling IT and business users to create or customize solutions that integrate with existing IT infrastructure to address varied investigative analytics, search and discovery, risk and compliance needs.

At Bio-IT World, Ben Szekely vice president solutions from Cambridge Semantics and Christine Blazynski chief science officer and senior vice president, new product development at Citeline (part of the Informa group), will be co-presenting and discussing the Smart Data Lake solution, April 22nd at 5:15 p.m.

Additionally, Cambridge Semantics will be exhibiting the solution at Booth #336 during exhibition hours April 21-23.

Bio-IT World takes place at the Seaport World Trade Center (200 Seaport Boulevard) in Boston, Mass. from April 21 until April 23, 2015.

About Bio-IT World

Part of the Cambridge Healthtech Institute Media Group (http://www.chimediagroup.com), Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Through a variety of sources including, Bio-ITWorld.com, Weekly Update Newsletter and the Bio-IT World News Bulletins, Bio-IT World is a leading source of news and opinion on technology and strategic innovation in the life sciences, including drug discovery and development.

About Informa PLC

Informa operates at the heart of the Knowledge and Information Economy. It is one of the world’s leading business intelligence, knowledge, and events businesses, with more than 6,000 employees in over 100 offices across 25 countries. To learn more, visit http://www.informa.com.

Clinical and commercial users in the pharmaceutical industry make key business decisions supported by actionable intelligence found in Informa’s R&D intelligence solutions such as Citeline’s Trialtrove and Sagient’s BioMedTracker.

About Cambridge Semantics

Cambridge Semantics (CSI), the Smart Data Company, is an enterprise analytics and data management company. It enables customers and partners to rapidly build interactive, real-time smart data solutions based on its Anzo Smart Data Platform (Anzo SDP).

IT departments and business users gain better understanding and data value through the semantic linking, analysis and management of diverse data whether internal or external, structured or unstructured. The Anzo SDP smart data solutions are delivered with increased speed, at big data scale and at the fraction of the implementation costs of using traditional approaches.

The company is based in Boston, Massachusetts.

For more information visit http://www.cambridgesemantics.com or follow us on Facebook, LinkedIn and Twitter: @CamSemantics.







Atelectasis Therapeutics Clinical Trial Market H2 2014 Review Report at ReportsnReports.com


Dallas, TX (PRWEB) December 29, 2014

The report “Atelectasis Global Clinical Trials Review H2 2014” provides data on the Atelectasis clinical trial scenario. The report It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Partial or complete collapse of lung is known as atelectasis. This condition develops when tiny air sacs known as alveoli in lungs gets deflated. Symptoms of atelectasis include difficulty in breathing, chest pain, coughing, fever and rapid breathing. This condition is most common among people who had surgery. Elderly people and smokers are at an increased risk of developing atelectasis. The condition is usually diagnosed via chest X-ray, bronchoscopy and computed topography. Treatment for atelectasis depends upon the underlying cause for the condition. Complete Report is Available @ http://www.reportsnreports.com/reports/320852-atelectasis-global-clinical-trials-review-h2-2014.html .

Scope

    Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
    Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
    Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Buy

    Understand the dynamics of a particular indication in a condensed manner
    Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
    Obtain discontinued trial listing for trials across the globe
    Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a Purchase copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=251694 .

Table of Contents

List of Tables

Atelectasis Therapeutics, Global, Clinical Trials by Region, 2014

Atelectasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014

Atelectasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, Europe, Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, North America, Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014

Proportion of Atelectasis to Respiratory Clinical Trials, G7 Countries (%), 2014

Atelectasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014

Atelectasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014

Proportion of Atelectasis to Respiratory Clinical Trials, E7 Countries (%), 2014

Atelectasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014

Atelectasis Therapeutics, Global, Clinical Trials by Phase, 2014

Atelectasis Therapeutics, Global, Clinical Trials In Progress by Phase 2014

Atelectasis Therapeutics, Global, Clinical Trials by Trial Status, 2014

Atelectasis Therapeutics Clinical Trials, Global, by End Point Status, 2014

Atelectasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013

Atelectasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dresden University of Technology, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital Sirio-Libanes, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Utah, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by London Health Sciences Centre, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Herlev Hospital, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oklahoma, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Medicine and Dentistry New Jersey (Inactive), 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014

Atelectasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014

List of Figures

Atelectasis Therapeutics, Global, Clinical Trials by Region (%), 2014

Atelectasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014

Atelectasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014

Atelectasis Therapeutics Clinical Trials, Europe, Top Countries (%), 2014

Atelectasis Therapeutics Clinical Trials, North America, Top Countries (%), 2014

Proportion of Atelectasis to Respiratory Clinical Trials, G7 Countries (%), 2014

Atelectasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014

Atelectasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014

Proportion of Atelectasis to Respiratory Clinical Trials, E7 Countries (%), 2014

Atelectasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014

Atelectasis Therapeutics, Global, Clinical Trials by Phase (%), 2014

Atelectasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014

Atelectasis Therapeutics, Global, Clinical Trials by Trial Status, 2014

Atelectasis Therapeutics Clinical Trials, Global, by End Point Status, 2014

Atelectasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013

Atelectasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.






Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Categories

Coursera

New Skills, New You: Transform your career in 2016 with Coursera

Follow us on Twitter